一线联合化疗后替吉奥维持治疗晚期胃癌24例临床分析  

Clinical observation of combination chemotherapy with subsequent S-1 maintenance chemotherapy for patients with advanced gastric cancer:Report of 24 cases

作　　者：黄莎[1] 范南峰[1] 李惠[1] 杨建伟[1] 

机构地区：[1]福建省肿瘤医院腹部肿瘤内科,福州350014

出　　处：《福建医药杂志》2013年第5期87-89,共3页Fujian Medical Journal

摘　　要：目的 探讨晚期胃癌联合化疗后继续替吉奥维持化疗的有效性与安全性.方法 对24例初治晚期胃癌患者,采用氟尿嘧啶和亚叶酸钙联合紫杉醇和奥沙利铂（POF）方案化疗,6～8周期疗效评价无疾病进展后,进行替吉奥维持化疗,维持化疗持续到疾病进展或出现不能耐受毒性为止.结果 24例患者均可评价疗效.部分缓解4例,疾病稳定15例,疾病进展5例.总有效率为16.7％,疾病控制率为79.1％,中位无进展生存时间为10.1个月,中位总生存时间为16.1个月.主要的不良反应有恶心、呕吐、腹泻、骨髓抑制、皮肤色素沉着、肝功能损伤等,经对症治疗后均好转,无治疗相关死亡.结论 POF方案一线化疗后替吉奥维持治疗晚期胃癌疾病控制率高,不良反应可耐受.Objective To investigate the efficacy and safety of S-1 maintenance chemotherapy after the first-line combination chemotherapy for patients with advanced gastric cancer. Methods Advanced gastric cancer patients received paclitaxel 135 mg/m2 followed by oxaliplatin 85 mg/m2 and LV 400 mg/m2 , then 5-FU 2400mg/m2 （46-hour infusion） every 14 days. A maximum eight-cycle dosage was given. A total of 24 patients who responded to the therapy received S-1 maintenance chemotherapy. The maintenance therapy continued until disease progression or intolerable toxicity. Results All patients were evaluated for the therapeutic efficacy. Four cases were in PR, 15 cases in SD, 5 cases in PD. The response rate was 16.7%, and the disease control rate was 79.1%. The median progress-free survival was 10.1 months, and the median overall survival was 16.1 months. The most common adverse events included nausea, vomiting, diarrhea, myelosuppression, liver function damage and skin pigmentation. Conclusion S-1 maintenance chemotherapy for advanced gastric cancer has high disease control rates, and the adverse events is well tolerated. Further evaluation of the efficacy of S-1 maintenance chemotherapy is needed.

关 键 词：胃癌 替吉奥 维持治疗 

分 类 号：R735.2[医药卫生—肿瘤]